## Hit Discovery

- Discovery of chemical start points using various methods, including:
  - Phenotypic (whole-cell)
  - Screening against molecular targets
  - Modification of existing compounds

## Lead optimisation

- Multi-parametric optimisation for potency, selectivity, physiochemical and pharmacokinetic properties, and non-clinical safety properties.

## Preclinical

- Good manufacturing process (GMP) scale-up and good regulatory practice (GRP) toxicology

## Clinical

- Phase 1: Pharmacokinetics and tolerability in healthy human volunteers.
- Phase 2: Proof of concept in patients.
- Phase 3: Large efficacy and safety study in patients.

## Registration

- Phase 4: Post-market surveillance.